Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ADPT vs BHVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADPT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–3 Matrix Metrics)

ADPT Overall Winner 6-Pillar Tally: ADPT 4 – 2 BHVN Matrix Metrics: ADPT 5 – 3 BHVN

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ADPT carries a Unified Composite Score of 43.8/100 (HOLD) at $27.94 (N/M Forward P/E, -16.2% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.4); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADPT vs BHVN
ADPT NASDAQ Head-to-Head Winner
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$27.94
-3.79% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.74β · 60% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 52
RSI-14: 52.4 · SMA20: $27.26 · SMA50: $26.98
BHVN NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.95
+0.9% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.40β · 111% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 48.4 · SMA20: $14.55 · SMA50: $13.48

6-Pillar Scorecard Institutional Category Breakdown (ADPT 4 – 2 BHVN)

Columns: Metric · ADPT · BHVN
1. Valuation Multiples ADPT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 16.8x N/M
2. Growth & Scale BHVN
Revenue Growth (YoY) -10.7% +0.0%
Earnings Growth (YoY) -70.1% +0.0%
TTM Revenue (USD) $298M N/A
Market Cap $4.7B $2.1B
3. Profitability & Quality BHVN
Gross Margin 46.2% N/A
Operating Margin -16.2% 0.0%
Net Profit Margin -23.7% 0.0%
Return on Equity (ROE) -36.4% -799.5%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) -$8.8M -$473M
Cash Flow Margin -3.0% N/A
Net Cash / Leverage $333M Net Debt (2.32x D/E) $205M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 74.2% (32nd %ile) 91.5% (18th %ile)
Put/Call OI Skew N/A 0.31x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat ADPT
OpEx & R&D Intensity 62.4% of Rev ($186M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADPT (5) vs BHVN (3)
Institutional Metric ADPT BHVN Criterion Row Edge
Market Capitalization
Scale
$4.7B $2.1B Larger Scale ADPT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-10.7% +0.0% Higher Growth BHVN
Operating Margin (TTM)
Profitability
-16.2% 0.0% Higher Margin BHVN
Net Profit Margin
Profitability
-23.7% 0.0% Higher Margin BHVN
Return on Equity (ROE)
Capital Efficiency
-36.4% -799.5% Higher ROE ADPT
52-Week Range Position
Momentum
79% ($12–$32) 59% ($8–$18) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
1.74β · 60% Vol 1.40β · 111% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite ADPT
Trailing 12M Revenue (USD)
Operating Scale
$298M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.8M ($333M Net Debt (2.32x D/E)) -$473M ($205M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +13.04 pp
ADPT: +16.32% · BHVN: +29.36%
3M Horizon ADPT +11.0 pp
ADPT: +13.76% · BHVN: +2.76%
6M Horizon ADPT +55.58 pp
ADPT: +119.83% · BHVN: +64.25%
1Y Horizon ADPT +25.01 pp
ADPT: +97.6% · BHVN: +72.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADPT vs BHVN. Trailing 12-month operating profitability (ADPT -16.2% vs BHVN 0.0%) and valuation multiples (ADPT N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ADPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$298M
Gross Margin46.2%
Op. Margin-16.2%
ROE / Fwd P/E-36.4% · N/M
BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADPT CONSOLIDATION
69d in phase · OBV ACCUMULATION
Current IV 74.2%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADPT vs BHVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ADPT carries a Unified Composite Score of 43.8/100 (HOLD) at $27.94 (N/M Forward P/E, -16.2% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.4); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHVN leads the Growth & Scale pillar: ADPT posts -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ADPT generates $298M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, ADPT deploys 62.4% of Rev ($186M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.

ADPT screens cheaper on headline valuation multiples. ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (-3.0% FCF margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADPT (-36.4% ROE) versus BHVN (-799.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ADPT carries 74.2% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 60% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.40β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.